Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
13.62
-1.20 (-8.07%)
At close: Nov 12, 2026, 4:00 PM EST
13.63
+0.01 (0.07%)
Pre-market: Nov 13, 2026, 4:02 AM EST

Trevi Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-70.13-49.33-51.52-33.92-29.91-32.48
Net Income
-60.76-42.76-47.91-29.07-29.15-33.94
Earnings Per Share
-0.40-0.32-0.47-0.29-0.45-1.49
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
299.41188.26107.6282.97120.5136.83
Total Debt
0.530.751.031.349.1814.74
Net Cash (Debt)
298.88187.51106.5981.63111.3322.09
Net Cash Growth
53.98%75.91%30.57%-26.68%404.06%-28.27%
Net Cash Per Share
1.971.391.050.821.720.97

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-61.44-42.09-38.26-31.71-28.18-28.95
Capital Expenditures
-0.25-0.01-0.04-0.14-0.16-
Free Cash Flow
-61.69-42.1-38.29-31.85-28.33-28.95
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.